Innate Pharma (IPHA) Long-Term Debt Repayments (2019 - 2024)
Historic Long-Term Debt Repayments for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to -$9.5 million.
- Innate Pharma's Long-Term Debt Repayments fell 27590.01% to -$9.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$16.5 million, marking a year-over-year decrease of 7120.88%. This contributed to the annual value of -$2.2 million for FY2019, which is 3990.92% down from last year.
- According to the latest figures from Q4 2024, Innate Pharma's Long-Term Debt Repayments is -$9.5 million, which was down 27590.01% from -$2.5 million recorded in Q4 2023.
- Innate Pharma's 5-year Long-Term Debt Repayments high stood at -$2.1 million for Q4 2022, and its period low was -$9.5 million during Q4 2024.
- Moreover, its 5-year median value for Long-Term Debt Repayments was -$2.5 million (2023), whereas its average is -$3.8 million.
- As far as peak fluctuations go, Innate Pharma's Long-Term Debt Repayments soared by 1266.88% in 2022, and later tumbled by 27590.01% in 2024.
- Quarter analysis of 5 years shows Innate Pharma's Long-Term Debt Repayments stood at -$2.7 million in 2020, then increased by 11.57% to -$2.4 million in 2021, then increased by 12.67% to -$2.1 million in 2022, then fell by 22.9% to -$2.5 million in 2023, then tumbled by 275.9% to -$9.5 million in 2024.
- Its Long-Term Debt Repayments stands at -$9.5 million for Q4 2024, versus -$2.5 million for Q4 2023 and -$2.1 million for Q4 2022.